Survival analysis of ninety-nine patients who received DeltaRex-G with or without DeltaVax, a tumor targeted retrovector encoding a granulocyte-macrophage colony stimulation factor (GM-CSF) gene showed 5% 10-year overall survival rate for patients who received DeltaRex-G alone, and 18.8% for DeltaRex-G + DeltaVax (Liu et al., 2021). This evidence concerns the gene CSF2 and neoplasm.